Ultragenyx Pharmaceutical (RARE) Misses Q3 EPS by 4c

Ultragenyx Pharmaceutical (NASDAQ: RARE) reported Q3 EPS of ($0.50), $0.04 worse than the analyst estimate of ($0.46).

For earnings history and earnings-related data on Ultragenyx Pharmaceutical (RARE) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
• Isabella Bank added to Russell 2000 index after Nasdaq listing